# Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

> **NCT00070096** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 29 (estimated)

## Conditions studied

- Brain and Central Nervous System Tumors
- Extragonadal Germ Cell Tumor
- Ovarian Cancer
- Testicular Germ Cell Tumor

## Interventions

- **DRUG:** ixabepilone

## Key facts

- **NCT ID:** NCT00070096
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070096, "Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00070096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*